Blinatumomab
Therapeutic Blinatumomab antibody from the original Blincyto® commercial drug.
Reference Standard as Aliquots
Blincyto®
Filters
Sort results
Reset
Apply
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot | Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2027.07 |
Blincyto® CH |
0.002 mg |
Unit: aliquot(s) |
788,00 €/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Blincyto® / Blinatumomab Reference Product
| Drug name | Blyncito® |
| INN | Blinatumomab |
| API type | Blinatumomab is produced in Chinese hamster ovary cells by recombinant DNA technology. |
| Pharmacotherapeutic group | Antineoplastic agents, other Antineoplastic agents |
| ATC code | L01XC19 |
| Target of antibody | CD19, CD3 |
| General function | Blinatumomab is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Blinatumomab is indicated as monotherapy for the treatment of adults and patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Blinatumomab is a bispecific T-cell engager molecule that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. The anti-tumour activity of blinatumomab immunotherapy is not dependent on T-cells bearing a specific TCR or on peptide antigens presented by cancer cells, but is polyclonal in nature and independent of human leukocyte antigen (HLA) molecules on target cells. Blinatumomab mediates the formation of a cytolytic synapse between the T-cell and the tumour cell, releasing proteolytic enzymes to kill both proliferating and resting target cells. Blinatumomab is associated with transient upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, and results in elimination of CD19+ cells. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Consistent immune-pharmacodynamic responses were observed in patients studied. During the continuous intravenous infusion over 4 weeks, the pharmacodynamic response was characterised by T-cell activation and initial redistribution, rapid peripheral B-cell depletion, and transient cytokine elevation. |
| Original license holder | Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands |
| Marketing authorisation numbers | EU/1/15/1047/001 |
| Marketing authorisation holder | Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands |
| Name of the manufacturer of the biological active substance | Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands |
| Name and address of the manufacturer(s) responsible for batch release | Amgen NV Telecomlaan 5-7 1831 Diegem Belgium |
| Max shelf life | 5 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Citric acid monohydrate (E330) Trehalose dihydrate Lysine hydrochloride Polysorbate 80 Sodium hydroxide (for pH-adjustment) |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
